MedTrace Logo

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)

NCT01760148 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2013-01-04

No results posted yet for this study

Summary

The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.

Conditions

Interventions

DRUG

interferon alpha 2b

Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection. Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Junqi Niu

    lead OTHER

Principal Investigators

  • Bing Sun, Doctor · Chinese Academy of Sciences

  • Chen Yang, Doctor · Chinese Academy of Sciences

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01760148 on ClinicalTrials.gov